Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Quonnie who wrote (427)	1/19/1999 6:13:00 PM
From: Anthony Wong	Respond to of 942

Quonnie, from PFE's earnings report: Lipitor Introduction In 1997, Pfizer helped Warner-Lambert Co. introduce the cholesterol reducer Lipitor. The drug quickly stole market share from older, more-established rival products from Merck & Co. and Bristol-Myers Squibb Co. because it appears to lower LDL cholesterol more. High levels of LDL, or so-called bad cholesterol, have been linked to heart disease. Lipitor's 1998 sales are expected to top $2 billion. Warner- Lambert will report its full 1998 results Monday. ''Merck and Bristol convinced everyone that lowering LDL was good and then Warner-Lambert came out with a drug that lowers LDL even more,'' said Alex Zisson, an analyst with Hambrecht & Quist. In the fourth quarter, Pfizer's revenue from its alliances with Warner-Lambert and Japan's Eisai Co. rose 83 percent to $299 million. Pfizer helps sell Eisai's Alzheimer's disease medicine, Aricept. news.com